AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Two-part Safety, Tolerability, Pharmacodynamic and -Kinetic Study of Inhaled AZD8871 in Asthmatic and COPD Subjects
Phase 1
Completed
- Conditions
- Asthma (Part 1)COPD (Part 2)
- Interventions
- Drug: Treatment A, AZD8871 dose A (Part 2)Drug: Dose 2, AZD8871 100 μg (Part 1)Drug: Dose 3, AZD8871 300 μg (Part 1)Drug: Dose 1, AZD8871 50 μg (Part 1)Drug: Dose 4, AZD8871 600 µg (Part 1)Drug: Dose 6, AZD8871 1800 μg (Part 1)Drug: Treatment B, AZD8871 dose B (Part 2)Drug: Placebo, AZD8871 placebo (Part 1)Drug: Treatment C, Indacaterol 150 μg (Part 2)Drug: Dose 5, AZD8871 1200 µg (Part 1)Drug: Treatment D, Tiotropium 18 μg (Part 2)
- First Posted Date
- 2015-10-09
- Last Posted Date
- 2018-11-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 134
- Registration Number
- NCT02573155
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
A Drug-drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants
- First Posted Date
- 2015-10-05
- Last Posted Date
- 2019-11-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 60
- Registration Number
- NCT02568397
- Locations
- 🇺🇸
Covance, Dallas, Texas, United States
Foxiga Korea Local Phase 4 Study
Phase 4
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2015-10-01
- Last Posted Date
- 2019-08-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 125
- Registration Number
- NCT02564926
- Locations
- 🇰🇷
Research Site, Wonju-si, Korea, Republic of
Effectiveness of Statins on Lipid Goal Attainment and Lipid Parameters in PCI Patients
- First Posted Date
- 2015-09-28
- Last Posted Date
- 2016-05-11
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT02561845
A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer
Phase 1
Terminated
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2015-09-28
- Last Posted Date
- 2019-02-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 15
- Registration Number
- NCT02561832
- Locations
- 🇪🇸
Research Site, Zaragoza, Spain
A Study to Compare the Pharmacokinetics of Different Formulations of AZD9977 and the Influence of Food in Healthy Male Subjects
Phase 1
Withdrawn
- Conditions
- PharmacokineticsFood EffectHealthy Male SubjectsSafety
- Interventions
- Drug: AZD9977 immediate release (IR) oral suspensionDrug: AZD9977 extended release (ER) capsules [fast]Drug: AZD9977 extended release (ER) capsules [intermediate]Drug: AZD9977 extended release (ER) capsules [slow]
- First Posted Date
- 2015-09-25
- Last Posted Date
- 2016-01-11
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT02560363
- Locations
- 🇬🇧
Research Site, Harrow, United Kingdom
Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma
Phase 2
Completed
- Conditions
- Metastatic Pancreatic Ductal Adenocarcinoma
- Interventions
- Drug: MEDI4736 monotherapyDrug: tremelimumab+MEDI4736
- First Posted Date
- 2015-09-24
- Last Posted Date
- 2018-08-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 65
- Registration Number
- NCT02558894
- Locations
- 🇪🇸
Research Site, Madrid, Spain
DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- First Posted Date
- 2015-09-17
- Last Posted Date
- 2018-12-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 3732
- Registration Number
- NCT02552160
- Locations
- 🇩🇪
Research Site, Zwoenitz, D6570r00001, Germany
Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer
Phase 3
Completed
- Conditions
- Squamous Cell Carcinoma of the Head and Neck
- Interventions
- Biological: CetuximabBiological: MEDI4736Biological: TremelimumabBiological: MEDI4736+Tremelimumab
- First Posted Date
- 2015-09-16
- Last Posted Date
- 2021-10-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 823
- Registration Number
- NCT02551159
- Locations
- 🇻🇳
Research Site, Ho Chi Minh city, Vietnam
A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin
Phase 3
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2015-09-16
- Last Posted Date
- 2018-12-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 650
- Registration Number
- NCT02551874
- Locations
- 🇸🇪
Research Site, Uddevalla, Sweden